Glycopyrronium-bromid - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

breztri aerosphere 160/7.2/5 budesonide 160 mcg/glycopyrronium 7.2 mcg/formoterol fumarate dihydrate 5 mcg per actuation inhalation pressurised metered dose inhaler

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

breztri aerosphere 160/7.2/5 budesonide 160 mcg/glycopyrronium 7.2 mcg/formoterol fumarate dihydrate 5 mcg per actuation inhalation pressurised metered dose inhaler (dfp-evocap)

Australia - English - Department of Health (Therapeutic Goods Administration)

robinul glycopyrronium bromide (glycopyrrolate) 0.4mg/2ml injection vial

aspen pharmacare australia pty ltd - glycopyrronium bromide, quantity: 0.2 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sodium chloride - 1.as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. 2.as a preoperative or intraoperative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxa-methonium or due to cardiac vagal reflexes. 3.to protect against the peripheral muscarinic actions (eg. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by nondepolarising muscle relaxants.